•
Dec 31, 2020
Insulet Q4 2020 Earnings Report
Insulet reported an 18% increase in revenue for Q4 2020, marking the 5th consecutive year of over 20% revenue growth.
Key Takeaways
Insulet Corporation reported a strong finish to 2020 with an 18% increase in revenue for the fourth quarter, reaching a record quarterly revenue of $246.1 million. The company also celebrated a milestone of 250,000 global customers using the Omnipod System.
Q4 2020 revenue increased by 17.5% to $246.1 million.
Total Omnipod revenue increased by 20.1% to $231.1 million.
U.S. Omnipod revenue increased by 17.8% to $149.2 million.
International Omnipod revenue increased by 24.5% to $81.9 million.
Insulet
Insulet
Insulet Revenue by Segment
Forward Guidance
For the year ending December 31, 2021, the Company expects revenue growth in the range of 15% to 20%. For the quarter ending March 31, 2021, the Company expects revenue growth of 20% to 24%.
Positive Outlook
- Total Omnipod of 17% to 21%
- U.S. Omnipod of 21% to 25%
- International Omnipod of 10% to 15%
- Drug Delivery of (11)% to 4%
- Operating margin in the low double digits range.
Revenue & Expenses
Visualization of income flow from segment revenue to net income